ArticleCancer immunology, immunotherapy : CII2025
Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosis.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Digital immune twins and ai-integrated multi-omic biomarkers: Redefining personalized immunotherapy in non-small cell lung cancer.Iranian journal of basic medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeoantigen-specific immune responses may help prevent cancer recurrence. We evaluated whether neoantigen load and/or properties could predict survival in early-stage non-small cell lung cancer (NSCLC).
methodsWhole-exome sequencing (WES) data from 89 resected early-stage NSCLC patients were used to identify non-synonymous single-nucleotide variants (nsSNV) and to predict major histocompatibility complex class I neoantigens. Neoantigen load, differential aggretopicity index (DAI), neoantigen frequency (number of neoantigens per nsSNV) and neoantigen promiscuity (ability to bind multiple human leucocyte antigen (HLA) alleles) were assessed for association with time to recurrence (TTR) and recurrence-free survival (RFS).
resultsHigher neoantigen load was independently associated with longer TTR (p = 0.028). A greater number of neoantigens with high DAI (≥ 10) were associated with improved TTR (p = 0.008) whilst increased neoantigen promiscuity correlated with both longer TTR (p = 0.007) and RFS (p = 0.010). Conversely, elevated neoantigen frequency predicted a worse prognosis (TTR p = 0.016).
conclusionsThese data support a role for T cells in on-going immunosurveillance in resected NSCLC patients and suggest that both quality and quantity of neoantigens are important drivers of anti-cancer immunity and may inform future biomarker and immunotherapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.